This article reviews the evidence for validity of symptom-based criteria (Manning, Rome I, Rome II, and Rome III) for irritable bowel syndrome (IBS). Two kinds of validations are reported: (i) studies testing whether symptom criteria discriminate patients with structural disease at colonoscopy from patients without structural disease; and (ii) studies testing whether symptom criteria discriminate patients presumed to have IBS by positive diagnosis from healthy subjects or patients with other functional and structural disorders. The fi rst study type addresses an important clinical management question but cannot provide meaningful information on the sensitivity or positive predictive value because IBS is defi ned only by exclusion of structural disease. Specifi city is modest (about 0.7) but can be improved to 0.9 by the addition of red fl ag signs and symptoms. The second type of study judges validity by whether the symptom criteria consistently perform as predicted by theory. Here, factor analysis confi rms consistent clusters of symptoms corresponding to IBS; symptom-based criteria agree reasonably well (sensitivity, 0.4 -0.9) with clinical diagnoses made by experienced clinicians; and patients with a clinical diagnosis of IBS who fulfi ll Rome II criteria have greater symptom severity and poorer quality of life than patients with a clinical diagnosis of IBS who do not fulfi ll Rome criteria. There are no consistent differences in sensitivity or specifi city between Manning, Rome I, and Rome II. Both study types support the validity of symptom-based IBS criteria. Tests of Rome III are needed .
INTRODUCTION
Th e irritable bowel syndrome (IBS), one of several functional gastrointestinal (GI) disorders ( 1 ) , is a highly prevalent and potentially disabling condition that is diagnosed by the pattern of symptoms that patients present to their physicians. Some critics have questioned whether the IBS and other functional GI dis orders truly exist as they do not have defi ning structural features ( 2 ) . Th e question of their existence is of little relevance to clinicians and patients who have to manage these symptoms on a day-to-day basis. However, for the purpose of research, we need to have a reliable and standard method to properly select patients to learn about the specifi c pathophysiological features underlying these symptoms, and to develop optimal treatment for targeted patient groups. For this reason, the Rome Foundation has fostered the use of symptom-based criteria ( 1 ) as has been done in psychiatry ( 3 ) , to aid in the more precise diagnosis of these common disorders for research and clinical care. Th is paper presents a critical review of the evidence that the existing criteria for IBS and other functional GI disorders are valid and clinically useful.
Several reviews and meta-analyses of studies that address the validity of symptom-based diagnostic criteria for the functional GI disorders have recently appeared ( 4 -7 ) . Nevertheless, controversy persists ( 6, 7 ) and there are repeated assertions that insufficient research has been done on the validity of these diagnostic criteria ( 6 ) . Th e goals of this review are to discuss the designs of these studies and the disease models on which they are based, to show how defi ciencies in some of these models have led to inconclusive results, and to suggest that the use of alternative disease models initially developed for the validation of diagnostic criteria for psychiatric disorders may be more appropriate for the functional GI disorders than the biological models used to date. Published studies based on these disease models will be summarized with a discussion of their implications for (i) the validity of the Rome symptom-based criteria, (ii) the importance of considering whether the symptom criteria are combined with physical examination and additional medical history fi ndings, and (iii) recommendations for future studies on the validity of the Rome criteria.
ASSUMPTIONS UNDERLYING VALIDATION STUDIES
IBS has an ICD9 ( 8 ) diagnostic code (564.1) and is regarded by most clinicians and most researchers as a discrete medical disorder for which pathophysiological bases are being identifi ed. Th ere is an acknowledged overlap with other functional GI ( 9,10 ), somatic ( 9 ) , and psychiatric disorders ( 11, 12 ) , and this observation has led some to speculate that IBS is not a distinct diagnostic entity ( 13 ) . However, most investigators interpret this overlap as an indication that IBS shares some etiologic features with other disorders ( 9, 11, 14 ) rather than seeing it as evidence that IBS is not a distinct medical disorder.
Th e model used in most validation studies is described as " concurrent validity " ( 15 ) . Th ese studies are designed to test how well a diagnostic marker or set of markers can distinguish between two groups of subjects, one of which is known to have the disorder in question (true positives) and the other of which does not have the disorder (true negatives). An example would be a test of the accuracy of breath hydrogen testing for small bowel bacterial overgrowth (SBBO) in which one assesses the ability of the breath test to distinguish between a group of subjects who are known to have SBBO based on microscopic examination of fl uid aspirated from the small bowel vs. a second group of subjects known to not have bacterial overgrowth based on the same objective standard ( 16 ) . Th is is a powerful design that permits the calculation of test statistics such as:
Sensitivity -the proportion of subjects with SBBO who are identifi ed by breath testing; Specifi city -the proportion of subjects without SBBO who are correctly classifi ed by a negative breath test; Positive likelihood ratio -the ratio of Sensitivity to (1 -Specifi city) [Specifi city is equivalent to the rate of misclassifi cation of subjects who do not have SBBO]; Negative likelihood ratio -the ratio of (1 -Specificity) to Sensitivity; Positive predictive value -the proportion of all subjects with a positive breath test who truly have SBBO; and Negative predictive value -the proportion of all subjects with a negative breath test who truly do not have SBBO.
Th e diffi culty with applying this model of concurrent validation to the symptom-based diagnostic criteria for IBS (or most other functional GI disorders) is that there is no independently verifi able gold standard diagnosis (i.e., there is no biomarker). In the absence of a gold standard, investigators have adopted either of the following two strategies
Defi ning IBS by exclusion
Th e most commonly used strategy is to test whether the diagnostic criteria for IBS allow one to correctly identify the subgroup of patients who are likely to have organic disease vs. a group who are unlikely to have an organic diagnosis if tested by endoscopy or other imaging modality ( 4, 5, 17 ) . Th is experimental design addresses a very important concern of the clinician, which is that he / she not miss a diagnosis such as infl ammatory bowel disease or cancer. However, because IBS is defi ned herein only by the exclusion of organic disease, it is not clear that the calculation of sensitivity, positive likelihood ratio, or positive predictive value have any meaning. On the other hand, estimates of specifi city (where specifi city is defi ned as identifying patients who have a signifi cant likelihood of endoscopically diagnosable organic disease), negative likelihood ratio, and negative predictive value do provide useful information on the relative safety of making a diagnosis of IBS based on the symptom criteria without recourse to endoscopy. Furthermore, when this approach (i.e., diagnosis by exclusion) is applied clinically, it can lead to cost-ineff ectiveness by overprescribing studies that are driven by patient requests and physician uncertainty ( 18 ) .
Defi ning IBS by positive symptom criteria
Other study designs are based on the assumption that IBS is a " real " medical disorder for which (i) pathophysiological features exist, albeit not fully delineated and (ii) it is currently possible to use positive symptom criteria to identify which subjects have this disorder. A successful example of this approach is found within psychiatry where symptom-based criteria identify diagnostic entities (e.g., posttraumatic stress disorder or anorexia nervosa) that " breed true " across clinical studies and cultural groups ( 3, 19, 20 ) . Although the pathophysiological determinants are not yet fully delineated, these conditions are readily identifi ed for research and can be specifi cally identifi ed in clinical practice and successfully treated. Th e developers of the Rome criteria view IBS and other functional GI disorders from this perspective and have consequently sought to identify symptom criteria that can distinguish IBS patients from healthy individuals as well as from patients with organic diseases or other functional disorders ( 21 ) .
A challenge that confronts investigators who believe that IBS patients have a specifi c medical disorder that is qualitatively different from health is that the symptoms that are used to identify patients with IBS also occur in healthy individuals; these are symptoms such as abdominal pain or discomfort and the occurrence of hard or loose stools in association with changes in abdominal pain or discomfort. Th us, the challenge is to identify thresholds for the frequency or intensity of occurrence of these symptoms that are clinically meaningful and that can distinguish patients presumed to have IBS from healthy controls. Attempts to address this challenge led the developers of the Rome III diagnostic criteria to measure these symptoms on frequency scales rather than presence / absence scales (which was done for Rome II and previous versions of the symptom-based diagnostic criteria) ( 22 ) . However, data are still needed for large groups of age-and sex-stratifi ed samples to provide an empirical basis for defi ning what is abnormal.
As noted, IBS is more similar to a psychiatric disorder, which is diagnosed from symptom features than it is to a structural disorder such as hepatitis or ulcerative colitis as no discrete morphological features or biomarkers exist. For disorders such as these, it is not possible to identify " true positives, " and eff orts to validate diagnostic criteria must rely on indirect strategies collectively referred to as " convergent validity " or sometimes simply as " predictive validity " ( 15 ) . Th e basic concept is that if a diagnostic indicator or questionnaire performs as you would predict it should based on the concept that IBS is a discrete medical disorder, this provides support that the diagnostic indicator is " valid. " When multiple predictions are confi rmed, the evidence for the validity of the diagnostic test is stronger. Consistent with this concept, the approaches taken by the Rome Foundation began with expert clinicians and investigators who classifi ed and categorized REVIEW more inclusive, allowing studies in which an organic diagnosis was inferred from alarm symptoms, and they analyzed 25 studies including all 10 studies analyzed by Ford ' s team.
Th e meta-analyses by Ford et al. ( 4 ) and Jellema et al. ( 5 ) yielded similar conclusions, namely that symptom-based criteria alone are only moderately helpful at identifying patients in whom there is a low likelihood of fi nding organic disease: Jellema et al. found the median specifi city (i.e., proportion of patients with organic disease who did not fulfi ll symptom criteria for IBS) to be 0.69 for the Manning criteria, 0.70 for the Rome I criteria, and 0.66 for the Rome II criteria. Medians for sensitivity (i.e., proportion of patients without organic disease who did fulfi ll the symptom criteria for IBS) were 0.67 for Manning, 0.72 for Rome I, and 0.69 for Rome II. Ford et al. reported an overall specifi city for the Manning criteria of 0.72 and an overall sensitivity of 0.78. Ford ' s team reviewed a single study using the Rome I criteria (36) , which had a specifi city of 0.85 and sensitivity of 0.71, but studies meeting their inclusion criteria were not available for Rome II. Th us, summary test statistics from these two reviews were very similar to each other and showed no signifi cant diff erences between Manning, Rome I, and Rome II criteria.
Combining " red fl ag " or alarm signs that suggest structural disease (e.g., blood in stool, abnormal blood test) along with GI symptoms improves accuracy for discriminating patients with a higher likelihood of having structural disease from patients with a low probability of such disease, compared with symptom criteria alone. Th is concept was fi rst proposed by Kruis over 25 years ago ( 37 ) , and was replicated in multiple studies ( 38 -44 ) . In a study by Vanner et al. ( 44 ) , for example, when patients with red fl ags (36 % of otherwise eligible patients) were excluded from the analysis, specifi city of the Rome I criteria was 100 % and sensitivity was 65 % . In summarizing the studies that have used this combined strategy, the meta-analysis by Jellema et al. ( 5 ) showed a median specifi city of 0.92 and sensitivity of 0.67, and meta-analysis by Ford et al. ( 4 ) showed a median specifi city of 0.87 and a sensitivity of 0.84. It should be noted, however, that when this combined strategy is used, most of the variance in risk of organic disease is related to the red fl ags and abnormal physical fi ndings, with minimal additional predictive power attributable to the addition of the symptom criteria ( 45 ) .
As alarm signs and symptoms can be easily incorporated into the offi ce-based diagnostic assessment of patients in primary care, this strategy for deciding which patients with lower GI symptoms should be referred for endoscopic evaluation and which may be safely managed without these tests is appealing. However, as shown by Whitehead et al. ( 43 ) , most red fl ag symptoms greatly overestimate the likelihood of organic disease. Th ese investigators found that 84 % of patients whom clinicians (80 % primary care, 20 % gastroenterology clinics) ultimately diagnosed as IBS reported one or more red fl ags. Vanner et al. ( 44 ) found a lower prevalence of 36 % with red fl ag symptoms in general gastroenterology clinics. As it may not be feasible to perform screening colonoscopies in all such patients, additional studies are needed that examine the sensitivity of individual red fl ags, alone and in combination, for predicting organic disease. diagnostic entities based on their clinical features ( 23 ) using a consensus-based " Delphi " approach ( 24, 25 ) . Once identifi ed, the conditions were refi ned and can now be validated by a variety of methods including: (i) epidemiological studies showing agreement in the prevalence of defi ned symptom groups across populations when using the same criteria ( 26, 27 ) ; (ii) the use of statistical methods such as factor analysis to identify frequently occurring clusters of symptoms, which can be compared with the Rome criteria ( 28, 29 ) ; and (iii) seeing whether the symptom criteria identify the patients who have been given a clinical diagnosis of IBS by experienced clinicians and discriminate them from patients diagnosed with other GI disorders ( 30 ) 
Statistical methods have been developed based on the concept of convergent validity and have been used to evaluate the accuracy of symptom criteria for psychiatric disorders ( 31 ) and gastroesophageal refl ux disease ( 32 ) . Th e most accessible of these statistical methods is latent class analysis ( 33 ), but Bayesian methods ( 34 ) , which are computationally more complex, have also been applied. Latent class analysis requires three or more diagnostic markers; it uses the correlation between pairs of diagnostic markers to estimate the sensitivity and specifi city of each for predicting the hypothetical variable, disease status. For example, Rome III criteria could be evaluated as one diagnostic marker alongside the results of colonoscopy and expert clinical opinion to predict IBS status. Th is statistical method off ers a possible approach to integrating validation studies based on the use of endoscopy to rule out organic disease with clinical markers such as symptom criteria and the diagnostic opinion of experienced clinicians. Th is method has not yet been applied to the validation of the Rome criteria but can be used in future studies.
OVERVIEW OF VALIDITY STUDIES THAT DEFINE IBS AS A DIAGNOSIS OF EXCLUSION
Two meta-analyses of the accuracy of symptom-based criteria for IBS have appeared in the past 2 years ( 4,5 ), and a third appeared 8 years ago ( 17 ) . A critical review of this evidence was included in the report of the American College of Gastroenterology IBS Task Force ( 35 ) . Since the Rome III criteria were published in 2006, these data can only summarize validation studies of symptom-based diagnostic criteria for IBS up to and including Rome II (published in 2000). Th ese meta-analyses were methodologically sound: they used quality criteria to select studies for inclusion and had two independent judges rate them. Th e meta-analysis by Ford et al. ( 4 ) used restrictive criteria including the requirement that patients be assessed for GI symptoms before colonoscopy, barium enema, or computed tomographic colography exams, which were used to exclude organic diagnoses; they identifi ed 10 studies eligible for analysis. As Jellema et al. ( 5 ) wished to include studies carried out in primary care in their meta-analysis, they were
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OVERVIEW OF VALIDITY STUDIES BASED ON THE ASSUMPTION THAT IBS IS A MEDICAL DISORDER ASSOCIATED WITH POSITIVE SYMPTOM CRITERIA
Symptoms cluster together in ways consistent with the Rome criteria . Some of the most compelling evidence for the validity of the symptom-based criteria for IBS comes from factor analysis studies. In 1990, Whitehead et al. ( 29 ) fi rst reported that when community samples of adults are given GI symptom checklists to complete, their symptoms tend to aggregate in clusters, that is, there are some symptoms that are more strongly correlated with each other than with any other GI symptoms. In this study and in multiple other studies by our group ( 28, 46, 47 ) and by others ( 48, 49 ) , the three symptoms that defi ne the symptom criteria for IBS have been found to cluster together. Th is cluster of symptoms is the same in males and females ( 47 ) , African Americans as well as Caucasian Americans ( 47 ), subjects from diff erent countries with distinct languages and cultures ( 28, 49 ) , and patients from GI clinics as well as population samples ( 28 ) . Factor analysis is also generally consistent with the symptom-based criteria for other functional GI disorders ( 28, 50, 51 ) , but the most robust evidence exists for IBS.
Agreement between physician diagnosis and symptom-based criteria . Four studies have reported the agreement between symptom-based diagnostic criteria and physician diagnosis ( Table 1 ) . In our view, clinical diagnosis cannot be viewed as a reliable gold standard because clinicians diff er based on their training and experience in how they defi ne IBS, and it is known that academic gastroenterologists, who see only a small fraction of IBS patients, are very familiar with the Manning and Rome criteria, whereas primary care physicians who manage an estimated 80 % of IBS patients are mostly unaware of symptom-based diagnostic criteria for IBS ( 52, 53 ) . Th us, one would not anticipate the agreement between symptom-based criteria and clinical diagnosis to be greater than about 0.70 because the agreement between pairs of clinicians is unlikely to be greater than this. Nevertheless, as one of the several measures of criterion validity, the agreement between clinical diagnosis and the symptom-based criteria is a reasonable choice. Th e sensitivity of the Rome II criteria compared with clinical diagnosis ( Table 1 ) ranged from 0.47 to 0.73, and specifi city ranged from 0.47 to 0.63. Two studies ( 53, 54 ) compared Rome I with Rome II criteria and showed signifi cantly greater sensitivity for Rome I compared with Rome II. Specifi city was not evaluated in these two studies. In three studies ( 43, 52, 54 ) , patients were diagnosed primarily or exclusively in primary care, whereas the fourth study ( 53 ) came from a tertiary gastroenterology practice. Th ere is some suggestion that sensitivity of the Rome II criteria was greater in tertiary care. Th ree other studies ( 42, 55, 56 ) that used symptom-based diagnostic criteria in clinical settings or epidemiological surveys were reviewed, but they did not provide estimates of the agreement between symptom-based diagnosis and clinical diagnosis.
Poorer quality of life impact and greater health-care utilization as a predictor of IBS . A relatively large group of patients whom clinicians have diagnosed IBS do not fulfi ll the IBS symptom criteria (see sensitivity statistics in Table 1 ). On the basis of the concept of predictive validity, one would expect that patients with a clinical diagnosis of IBS who fulfi ll Rome II criteria may have poorer health status compared with patients with a clinical diagnosis of IBS who do not fulfi ll Rome II criteria for IBS. In Table 2 , we show previously unpublished analyses of the study reported by Whitehead et al. ( 43 ) . Only patients who received a clinical diagnosis of IBS from their health-care provider at Group Health Cooperative are included in these analyses. As predicted, patients fulfi lling Rome II criteria for IBS have more severe symptoms of IBS, and they also have poor IBS-specifi c quality of life. Th e hypothesis that patients who fulfi ll Rome II criteria would make more health-care visits for GI complaints was not confi rmed; however, the failure to see a diff erence in the number of visits may relate to the fact that 
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positive diagnosis of IBS because the inclusion criteria largely determine who is defi ned as having IBS. Studies using this model show specifi cities of about 0.7, and based on this evidence, in the primary care setting where most IBS patients are managed and where the base rate of organic disease is known to be low, it is considered appropriate, in the absence of alarm symptoms or age over 50, to make a fi rm diagnosis based on symptom-based criteria without further physiological testing or colonoscopy. In the secondary and tertiary care settings where the base rate of organic disease is much higher, oft en approaching 50 % ( 4 ), these test statistics provide less reassurance and diagnostic testing may at times need to be performed. Th e specifi city of symptom-based criteria can be improved by combining them with laboratory tests, especially screening tests for infl ammation and blood in stools ( 37,39 -41,61 -63 ) . In these contexts, however, the laboratory tests are far more robust than the symptom criteria as predictors of who is at risk for organic disease. Incorporating patient-reported alarm symptoms into the diagnostic algorithm also yields small gains in specifi city ( 42, 44 ) , but excluding all patients with alarm symptoms from a diagnosis of IBS is impractical because 84 % of patients ultimately diagnosed IBS have one or more alarm symptoms ( 43 ) .
Validating positive symptom criteria for IBS on the assumption that it is a distinct medical disorder is diffi cult because there is no objective marker of IBS -IBS is a theoretical construct similar to psychiatric disorders, and the " convergent validity " methods used to validate diagnostic methods in psychiatry are also appropriate for functional GI disorders. Th is method relies on a converging set of studies testing the performance of the symptom-based diagnostic criteria against theoretical predictions. Th e symptom-based criteria for IBS are supported by (i) moderately good agreement with clinical diagnosis; (ii) evidence for clustering of symptoms consistent with Rome criteria based on factor analysis, and (iii) evidence that among patients with a medical diagnosis of IBS, those meeting Rome II criteria have worse health outcomes than those who do not. On the basis of this evidence, clinicians can use the Rome symptom criteria for IBS with reasonable confi dence that (i) patients who fulfi ll these symptom criteria are likely to benefi t from IBS-specifi c drugs and other treatments, and (ii) in the absence of alarm signs and symptoms, it is safe and appropriate to initiate treatment without referring for imaging studies to rule out organic disease. Th ese symptom criteria have been accepted by the Food and Drug Administration and the National Institutes of Health as inclusion criteria in trials based on this evidence of predictive validity, and this has accelerated the pace of discovery.
Future research on the validity of the Rome III criteria should pursue both of the validation models described here in parallel: on the one hand, we should continue to seek ways of identifying patients at low risk of organic disease by combining symptombased criteria with inexpensive laboratory tests available to the primary care physician as well as medical history items such as age, family history, symptomatic exacerbation following meals, and duration of illness. On the other hand, we should also pursue convergent validation of positive symptom criteria for IBS against health-care visits are prepaid in this HMO, which may lower the threshold for making health-care visits.
VALIDATION OF THE ROME III CRITERIA
Only one ( 22 ) published study has addressed the validity of the Rome III criteria: as reviewed, most studies have investigated the Manning criteria with a smaller number investigating the Rome I and Rome II criteria. Can one generalize from these studies and draw conclusions about the validity of the Rome III criteria? It needs to be understood that the symptom-based diagnostic criteria have evolved from each other: the same cluster of three painrelated symptoms form the core of the Rome I, II, and III criteria, and they are also present in the Manning criteria. Th us, all these diagnostic criteria should perform similarly. However, it is difficult to compare across studies because prevalence estimates diff er depending on which criteria are used ( 57 -59 ) and the sensitivity and specifi city of the criteria diff er when compared with clinical diagnosis ( 53, 54 ) and to a lesser extent when compared with the results of endoscopic examinations ( 4, 5 ) . Th us, when the Rome III criteria were compared with the Rome II criteria, signifi cantly diff erent prevalence estimates were seen ( 57, 58 ) , and there were diff erences in which patients were identifi ed as IBS ( 57 ) . However, one study comparing Rome II and Rome III criteria for IBS and its subtypes (IBS-C, D, M) within the same patient cohort showed excellent agreement (86.5 % , κ = 0.79), and the behavior of these patients were similar in terms of subtype prevalence and stability over a 1-year period ( 60 ) . Th us, it will be necessary in the future to perform validation studies specifi cally on Rome III criteria to fully address this question. However, the similarity of the question items and the evidence from at least one study comparing criteria from the same clinical cohort suggest that the evidence for the validity of Rome I and Rome II will also apply to Rome III.
SUMMARY AND FUTURE DIRECTIONS
Th e focus of most studies purporting to validate symptom-based diagnostic criteria for functional GI disorders has been to test whether symptomatic patients at high risk for infl ammatory bowel disease, GI cancer, or malabsorption can be discriminated from those at low risk. Th is study design defi nes IBS as the absence of structural diseases, and we believe this renders meaningless any estimates of the sensitivity of the symptom-based criteria for a 
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REVIEW new targets, which may include a variety of biomarkers such as visceral hyperalgesia, mucosal infl ammatory markers, genetic factors, alterations in microfl ora, and a variety of other possibilities yet to be determined. Statistical models such as latent class analysis ( 33 ) and Bayesian classifi cation ( 34 ) off er an unexplored opportunity to advance our understanding of the accuracy of the Rome criteria by integrating multiple candidate diagnostic markers. Th ese statistical methods should be incorporated into future tests of the validity of the Rome III diagnostic criteria. In addition, we need more normative data on the frequency of occurrence of symptoms such as abdominal pain that are used to diagnose functional GI disorders; these symptoms also occur in healthy individuals, and empirical data for defi ning clinically meaningful deviations from the healthy range are needed to better inform symptom-based diagnostic criteria. Validation of symptom-based criteria is a process; it is not etched in stone and will change as new data on its underlying pathophysiology emerges. Furthermore, the Rome Foundation is committed to supporting ongoing validation studies of symptom-based criteria to ultimately help our patients with these disorders .
